VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Duobrii
Phase 3
Small molecule
I
Icahn School of Medicine at Mount Sinai
1
Indications
3
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Biologics
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Biologics
Phase 3
Recruiting
Clinical
Trials by Indication
[1]
Psoriasis
1 trial
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Completed
·
I
Icahn School of Medicine at Mount Sinai
·
Phase 4
·
NCT04720105
·
22 enrolled
Keloid
1 trial
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
Terminated
·
I
Icahn School of Medicine at Mount Sinai
·
Phase 3
·
NCT05608499
·
15 enrolled
Biologics
1 trial
Duobrii in Combination With Biologics
Recruiting
·
P
Psoriasis Treatment Center of Central New Jersey
·
Phase 4
·
NCT04119102
·
25 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
3 trial records for Duobrii. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Duobrii compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Duobrii. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Icahn School of Medicine at Mount Sinai company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
I
Icahn School of Medicine at Mount Sinai
Related News